People with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and
hypertension than the general population. This results in an increased incidence of …

Background: The purpose of this study was to test prospectively the feasibility and efficacy of
a multimodal weight control program for overweight and obese severely mentally ill adults …

Objective: This 6-week trial assessed the efficacy, tolerability, and safety of the
investigational psychopharmacologic agent asenapine versus placebo and risperidone in …

Background Treatment during first-episode psychosis (FEP) or early schizophrenia may
affect the rates of relapse and remission, as well as cognitive functioning, over time …

Social dysfunction is a hallmark of schizophrenia. Social isolation may increase individuals'
risk for psychotic symptom exacerbation and relapse. Monitoring and timely detection of …

Guidelines for schizophrenia treatment have been created in various countries and have
been translated and used in Japan as well. However, the available drugs and their …

Antipsychotic effects seem to decrease in relapsed schizophrenia patients and the
underlying mechanisms remain to be elucidated. Based on the essential role of …

These guidelines for the biological treatment of schizophrenia were developed by an
international Task Force of the World Federation of Societies of Biological Psychiatry …

Abstract The Royal Australian and New Zealand College of Psychiatrists is co-ordinating the
development of clinical practice guidelines (CPGs) in psychiatry, funded under the National …

In this article we examine the two major classes of side effects with atypical antipsychotics:
extrapyramidal symptoms (EPS) and the metabolic syndrome (the triad of diabetes …